Aprea Therapeutics, Inc.

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics based on synthetic lethality mechanisms targeting DNA damage response pathways. The company's approach centers on identifying vulnerabilities in cancer cells by inhibiting specific molecular targets that render tumor cells dependent on alternative survival pathways. This mechanism aims to selectively kill cancer cells while minimizing impact on healthy cells.

The company's pipeline includes two primary product candidates. APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase, is currently in Phase 1 clinical development for patients with advanced solid tumors that express relevant biomarkers. ATRN-119, an ATR kinase inhibitor, is in Phase 1/2a clinical testing for solid tumor indications. Both candidates represent attempts to exploit DNA damage response vulnerabilities as a therapeutic strategy.

Aprea operates as a private development-stage entity with a small team of eight full-time employees, headquartered in Doylestown, Pennsylvania. The company is incorporated in Delaware and publicly listed on the Nasdaq exchange. As an early-stage clinical company, Aprea has not yet generated product revenue and remains dependent on capital funding and partnerships to advance its development programs.